Cargando…
Expert perspectives on biosimilar monoclonal antibodies in breast cancer
While biosimilars of low molecular-weight biologics such as G-CSF have been available in Europe since 2006, biosimilars of monoclonal antibodies (mAbs) have only become available in the last year. Unlike G-CSF, mAbs are large and complex and often play a direct role in the survival of patients with...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949011/ https://www.ncbi.nlm.nih.gov/pubmed/24562824 http://dx.doi.org/10.1007/s10549-014-2879-9 |